Compare Recursion Pharmaceuticals Inc (RXRX) vs Stitch Fix Inc (SFIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Stitch Fix Inc — how do they compare? Recursion Pharmaceuticals Inc trades at $3.22 (market cap $1.86B), while Stitch Fix Inc trades at $2.9 (market cap $396.27M). The key difference: Recursion Pharmaceuticals Inc is far larger — about 4.7× Stitch Fix Inc's market cap. Which is the better fit depends on your goals.
| RXRX | SFIX | |
|---|---|---|
Market Cap | $1.86B | $396.27M |
Sector | Health | Consumer Cyclical |
52-Week High | $6.79 | $5.80 |
52-Week Low | $2.84 | $2.89 |
Enterprise Value | $1.38B | $283.99M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
Stitch Fix (SFIX) trades at $2.97, down 2.62% on the day, as the stock faces technical bearish pressure despite showing fundamental improvements. The company has demonstrated progress in its turnaround with three consecutive quarterly earnings beats and narrowing losses, though it remains unprofitable with a -1.43% net margin. Recent news highlights ongoing legal challenges and AI-driven growth initiatives, while analyst sentiment remains cautious with 64% hold ratings.
The outlook suggests a company in transition - improving operational metrics and debt-free balance sheet provide stability, but sustained profitability remains the key challenge. Near-term catalysts include Q2 2026 earnings results and continued execution of AI personalization strategy, though competitive pressures and consumer spending volatility present ongoing risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Stitch Fix Inc
Stitch Fix Inc offers personal style service for men and women. The company engages in delivering one-to-one personalization to clients through the combination of data science and human judgment. It provides a shipment service called A FIX where the stylist's hand selects items from several merchandises with analysis of client and merchandise data to provide a personalized shipment of apparel, shoes, and accessories suited to the client's needs. The company offers products across categories, brands, product types and price points including Women's, Petite, Maternity, Men's and Plus. It also offers various product types, including denim, dresses, blouses, skirts, shoes, jewelry and handbags, and sells merchandise across various range of price points.
Read more on SFIX →
